Limited-Stage Hodgkin Lymphoma Minimizing Toxicity

被引:2
|
作者
Straus, David J. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Lymphoma Serv, 1275 York Ave,Box 330, New York, NY 10065 USA
[2] Weill Cornell Med, New York, NY USA
关键词
chemotherapy; combined modality; early-stage classic Hodgkin lymphoma; long-term toxicity; radiation; RADIATION-THERAPY; HEART-DISEASE; HD15; TRIAL; OPEN-LABEL; CHEMOTHERAPY; RADIOTHERAPY; RISK; ABVD; DACARBAZINE; TOMOGRAPHY;
D O I
10.1097/PPO.0000000000000329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
引用
收藏
页码:223 / 229
页数:7
相关论文
共 50 条
  • [41] Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes
    Kumar, Anita
    Burger, Irene A.
    Zhang, Zhigang
    Drill, Esther N.
    Migliacci, Jocelyn C.
    Ng, Andrea
    LaCasce, Ann
    Wall, Darci
    Witzig, Thomas E.
    Ristow, Kay
    Yahalom, Joachim
    Moskowitz, Craig H.
    Zelenetz, Andrew D.
    HAEMATOLOGICA, 2016, 101 (10) : 1237 - 1243
  • [42] Chemotherapy Only in Early Stage Hodgkin Lymphoma: More Relapses but the Same Survival - What to Do?
    Connors, Joseph M.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (03) : 217 - 221
  • [43] Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy
    Moding, Everett J.
    Advani, Ranjana
    Rosenberg, Saul A.
    Hoppe, Richard T.
    RADIOTHERAPY AND ONCOLOGY, 2018, 129 (03) : 507 - 512
  • [44] Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
    Kobe, Carsten
    Goergen, Helen
    Baues, Christian
    Kuhnert, Georg
    Voltin, Conrad-Amadeus
    Zijlstra, Josee
    Hoekstra, Otto
    Mettler, Jasmin
    Drzezga, Alexander
    Engert, Andreas
    Borchmann, Peter
    Dietlein, Markus
    BLOOD, 2018, 132 (21) : 2273 - 2279
  • [45] Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma
    Al-Jizani, Wafa'a A.
    Al-Mansour, Mubarak M.
    Al-Fayea, Turki M.
    Shafi, Ruaa U.
    Kazkaz, Ghieth A.
    Bayer, Ali M.
    Al-Foheidi, Meteb E.
    Ibrahim, Ezzeldin M.
    FUTURE ONCOLOGY, 2015, 11 (15) : 2149 - 2157
  • [46] Proton therapy for Hodgkin lymphoma
    Rutenberg, Michael S.
    Flampouri, Stella
    Hoppe, Bradford S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (03) : 203 - 211
  • [47] News in Hodgkin Lymphoma Therapy
    Brice, Pauline
    BULLETIN DU CANCER, 2014, 101 (01) : 68 - 74
  • [48] Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy
    Ermann, Daniel A.
    Vardell, Victoria A.
    Shah, Harsh
    Fitzgerald, Lindsey
    Tao, Randa
    Gaffney, David K.
    Stephens, Deborah M.
    Hu, Boyu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (02) : 94 - 104.e6
  • [49] Limited-stage diffuse large B-cell lymphoma
    Hawkes, Eliza A.
    Barraclough, Allison
    Sehn, Laurie H.
    BLOOD, 2022, 139 (06) : 822 - 834
  • [50] Treatment of early-stage Hodgkin lymphoma
    Engert, Andreas
    Raemaekers, John
    SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 165 - 170